FMP
Dec 09, 2025
On February 15, 2026, SOL Global Investments Corp., a significant stakeholder in Jones Soda Co. (OTC:JSDA), sold 20,000 Common Shares at $0.245 each. Despite this sale, SOL Global still holds a substantial 14,215,035 shares in JSDA. This transaction is part of the ongoing activities surrounding Jones Soda, a company known for its unique soda flavors and innovative marketing strategies.
Jones Soda Co. is making strategic changes to its executive team and financial plans. The company has appointed Darcey Macken as Chief Operating Officer and Eric Schnabel as Chief Marketing Officer. Macken, with over 20 years in consumer goods, previously led Planterra Foods, where she helped launch the OZO brand. These leadership changes aim to strengthen Jones Soda's market position and drive growth.
To support its growth initiatives, Jones Soda has increased its revolving credit facility from $5 million to $10 million. This financial move is designed to provide the company with more flexibility in executing its expansion plans. The increased credit facility will likely aid in the nationwide rollout of new products, such as the Fallout-themed Vault-Tec Supply Packs at Costco.
The Fallout-themed Vault-Tec Supply Packs have been a hit, selling out quickly in select locations. Due to high demand, Jones Soda, in collaboration with Costco, is expanding distribution nationwide. This follows a successful surge in online sales of the Sunset Sarsaparilla 4-packs, showcasing the brand's effective integration of gaming culture into its offerings.
JSDA's stock price has seen a notable increase, currently at $0.252, up 40% with a $0.072 change. The stock has fluctuated between $0.176 and $0.2875 today, with a market cap of approximately $29.65 million. The trading volume is 879,339 shares, reflecting strong investor interest in the company's recent developments and strategic initiatives.
Vertiv Holdings Co. (NYSE: VRT) is a prominent player in the technology sector, specializing in providing critical digit...
Kymera Therapeutics, listed on the NASDAQ as KYMR, is a biopharmaceutical company focused on developing novel protein de...